anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Colorectal cancer (CRC) involves various genetic alterations, with liver metastasis posing a significant clinical challenge. Furthermore, CRC cells mostly show an increase in resistance to traditional treatments like chemotherapy. It is essential to investigate more advanced and effective therapies to prevent medication resistance and metastases and extend patient life. As a result, it is anticipated that small interfering RNAs (siRNAs) would be exceptional instruments that can control gene expression by RNA interference (RNAi). In eukaryotes, RNAi is a biological mechanism that destroys specific messenger RNA (mRNA) molecules, thereby inhibiting gene expression. In the management of CRC, this method of treatment represents a potential therapeutic agent. However, it is important to acknowledge that siRNA therapies have significant issues, such as low serum stability and nonspecific absorption into biological systems. Delivery mechanisms are thus being created to address these issues. In the current work, we address the potential benefits of siRNA therapy and outline the difficulties in treating CRCby focusing on the primary signaling pathways linked to metastasis as well as genes implicated in the multi-drug resistance (MDR) process.
FIELD: organic chemistry. SUBSTANCE: invention relates to novel derivatives of aromatic amines of the general formula (1)   eliciting effect inhibiting OAC and to method of their synthesis and inhibitor of нOAC. Invention describes compounds of the general formula (1) where R 1 , R 2 , R 3 , R 4  have similar or different values and taken among hydrogen atom, lower alkyl possibly substituted with halogen atom, phenyl possible substituted with halogen atom, lower alkyl, cyclic alkyl group with 3-8 carbon atoms; or R 1  and R 2  can in common form 3-8-membered ring; or R 3  and R 4  in common form monocyclic or condensed ring with 3-10 carbon atoms; X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9  can be similar or different and taken among hydrogen atom and other values, respectively; A means substituted benzene or 5-6-membered aromatic heterocyclic ring possibly having substitutes; n and m each is a whole number = 0 or 1 under condition indicated in the invention claim or their possible tautomers, stereomers or optically active forms and pharmaceutically acceptable salt. Invention relates also to inhibitor of нOAC comprising the above indicated compounds and pharmaceutically acceptable carrier or diluting agent. Method of synthesis involves interaction of compound of the formula (2)   with compound A-у 1 , where Y and у 1  are different and mean NHR 5  or L where L is removal group. EFFECT: improved method of synthesis, valuable properties. 19 cl, 81 tbl
PANCREAZE is a mixture of enzymes including lipases, proteases, and amylases. PANCREAZE dosing is based on lipase units.

  * Use either an actual body weight or fat ingestion-based dosing scheme.
  * Start at the lowest recommended dosage and individualize the dosage based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet. Changes in dosage may require an adjustment period of several days.
  * Do not exceed 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in adult and pediatric patients greater than 12 months of age without further investigation [see Warnings and Precautions (5.1)] . 
  * The total daily dosage in adult and pediatric patients greater than 12 months of age should reflect approximately three meals plus two or three snacks per day. With each snack, administer approximately half the prescribed PANCREAZE dose for a meal.
  * Do not substitute other pancreatic enzyme products for PANCREAZE. When switching from another pancreatic enzyme product to PANCREAZE, monitor patients for clinical symptoms of exocrine pancreatic insufficiency and titrate the dosage as needed.
The present invention relates to novel biodegradable materials based on modified polyamino acids that can be used, in particular, for the vectorization of active principle(s) (PA). The invention also relates to novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on these polyamino acids. The objective of the invention is to provide a novel polymer starting material that is capable of being used for the AP vectorization and that makes it possible to optimally satisfy all the specifications required in the case in point: biocompatibility, biodegradability, ability to associate easily with numerous active principles or to dissolve them, and to release these active principles in vivo. This objective is achieved by the present invention, which relates to novel polyglutamates modified by cationic groups that, if they can be deprotonated, have a pKa greater than or equal to 7, and by hydrophobic groups comprising from 8 to 30 carbon atoms. These polyglutamates modified by cationic groups are capable of being easily and economically converted into particles for the vectorization of active principles, these particles being themselves capable of forming stable aqueous colloidal suspensions. These modified polyglutamates have the advantage of being less viscous than other similar polymers, while retaining an ability to associate proteins such as insulin. Some are soluble in water at acid pH and become insoluble at physiological pH (7.4) and should therefore, during a subcutaneous injection, precipitate at the injection site.
All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients will receive 0.9% normal saline instead of Tranexamic acid.
PROBLEM TO BE SOLVED: To obtain a cosmetic composition and/or food/drink each formulated with a new and safe anti-mutagenically active substance. SOLUTION: The anti-mutagenically active substance contains at least one kind of extract from plant(s) selected from bean sprouts, tangle, Eucheuma muricatum, Chondrus elatus and Ulva pertusa. New cosmetic composition and/or food/drink is obtained by formulating the above substance. This new substance has the ability to efficiently repair DNA mutation. The above new cosmetic composition and/or food/drink is intended for inhibiting or preventing genotoxicity, cancer, senile change, or the like. Furthermore, this new substance is hopeful of application to pharmaceutical development using the technologies in the fermentation industry, genetic engineering, or the like.
Study will investigate the long-term effects of repeated (20) sessions of home-based tDCS as an add-on to well-established remote LSVT (i.e. the gold standard procedure for HD treatment) as compared to LSVT alone (coupled with sham stimulation) in patients with PD in their "on" dopaminergic condition without dyskinesias.

A two parallel-group, double-blinded, randomized, sham-stimulation-controlled design will be used. Forty PD patients will be randomized into two parallel groups by independent researcher by a computer-generated random number list, 20 subjects in each arm. Participants in the real tDCS group and the sham tDCS group will undergo a baseline assessment (V0), a follow-up assessment after four weeks of combined tDCS and LSVT treatments (V1) and another follow-up assessment 8 weeks after the baseline assessment (V2). Each visit will consist of EEG, speech tasks recording and speech evaluation by a speech therapist; MR scanning will be done at V0 and V1. Both groups will undergo the same speech therapy (LSVT) via telepractice as the gold standard treatment for HD, in combination with real or sham tDCS.
Patients infected with AIDS can benefit from therapy with an effective anti-AIDS virus agent. AZT is a drug that is effective in inhibiting the effects of HIV infection. The study will show whether toxicity of AZT can be reduced in a more manageable treatment plan, and whether AZT therapy will delay the development of opportunistic infections and/or KS lesions.

Patients are divided into two treatment groups, the first receiving AZT for 5 doses a day, and the second receiving AZT for 3 doses per day. A placebo group is divided into two to match the two treatment groups. Study patients are stratified according to whether they have (a) 10 or fewer cutaneous lesions without oral lesions or (b) more extensive cutaneous lesions or oral lesions. Patients are seen on an outpatient basis weekly for the first 2 months, every other week for the next 2 months, and monthly thereafter.
The invention relates to synthesis and application of symmetrical boron fluoride fluorescent dye with A-D-A configuration, belonging to the field of fluorescent dye. The molecular structure is as follows: wherein r=h, CH  3  ，OCH  3  . At present, the fluorine boron fluorescent dye has a D-A structure, and reports of A-D-A fluorine boron fluorescent dye are not yet seen. The phenothiazine has strong electron supply capacity and is hopeful to conjugate with two electron acceptors to obtain A-D-A fluorescenceA dye. In addition, such fluoroboric dyes have long wavelength emission, large Stokes shift, high fluorescence quantum efficiency, and solid fluorescence properties as compared to conventional fluoroboric dyes. And the method can respond to HClO and has good biological application prospect.
5.1 Severe Skin and Hypersensitivity Reactions

Severe, potentially life-threatening, and fatal skin reactions have been reported. These include cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Hypersensitivity reactions have also been reported and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including hepatic failure. Discontinue ISENTRESS and other suspect agents immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema). Clinical status including liver aminotransferases should be monitored and appropriate therapy initiated. Delay in stopping ISENTRESS treatment or other suspect agents after the onset of severe rash may result in a life-threatening reaction.

5.2 Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including ISENTRESS. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jiroveci pneumonia, tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.

5.3 Phenylketonurics

ISENTRESS Chewable Tablets contain phenylalanine, a component of aspartame. Each 25 mg ISENTRESS Chewable Tablet contains approximately 0.05 mg phenylalanine. Each 100 mg ISENTRESS Chewable Tablet contains approximately 0.10 mg phenylalanine. Phenylalanine can be harmful to patients with phenylketonuria.
The trophoblast cells are responsible for the transfer of nutrients between the mother and the foetus and play a major role in placental endocrine function by producing and releasing large amounts of hormones and growth factors. Syncytiotrophoblast cells (STB), formed by the fusion of mononuclear cytotrophoblasts (CTB), constitute the interface between the foetus and the mother and are essential for all of these functions. We performed transcriptome analysis of human placental samples from two control groups-live births (LB), and stillbirths (SB) with a clinically recognised cause-and from our study group, idiopathic stillbirths (iSB). We identified 1172 DEGs in iSB, when comparing with the LB group; however, when we compared iSB with the SB group, only 15 and 12 genes were down- and upregulated in iSB, respectively. An assessment of these DEGs identified 15 commonly downregulated genes in iSB. Among these, several syncytiotrophoblast markers, like genes from the PSG and CSH families, as well as ALPP, KISS1, and CRH, were significantly downregulated in placental samples from iSB. The transcriptome analysis revealed underlying differences at a molecular level involving the syncytiotrophoblast. This suggests that defects in the syncytial layer may underlie unexplained stillbirths, therefore offering insights to improve clinical obstetrics practice.
Enrolled patients will be randomized to either the octreotide (sandostatin ) or the placebo group. The randomization process will be done using closed envelop method and will be withdrawn by a nurse after pancreaticoduodenectomy . Patients in the octreotide group will receive sandostatin 100ug SC every 8 hours daily staring from the day of operation to the postoperative day 7. Patients in the placebo group will receive saline administered in a similar manner.
Overcoming the burden of depression remains one of the most significant challenges in managing bipolar disorder. Compared to mania, depressive episodes in bipolar disorder are more frequent and considerably longer in length, with individuals spending roughly one-third to one-half of their lives suffering from depressive symptoms. Most of the difficulties with functioning at work, home, or school are due to depressive episodes, and most suicides occur in the context of a depressive (vs. manic) episode. Medication treatment of bipolar depression is not straightforward. Some individuals have a poor response to mood stabilizing medications, experience switches into mania as a result of antidepressant use, and have trouble taking their medications as prescribed. Thus, there remains a need for treatments that individuals with bipolar depression can use in addition to medication. As a practice that incorporates elements of physical exercise, controlled breathing, and meditation, hatha yoga has frequently been recommended as a way to manage bipolar disorder symptoms. There are numerous reasons why hatha yoga may be helpful for bipolar depression. First, there is some evidence that hatha yoga is useful for unipolar depression. Second, it is possible that yoga may help individuals with bipolar disorder regulate their daily routines, decrease negative depressive thoughts, and have a positive impact on biological mechanisms related to bipolar disorder. Yet to our knowledge, there have been no published studies on the benefits - and potential risks - of the practice of yoga in bipolar disorder. The primary aim of the proposed pilot study is to develop a 10 week yoga program specifically tailored to bipolar depression. We will develop an instructor manual for teaching classes and a scale for measuring instructor adherence to the manual. We will evaluate the feasibility, acceptability to patients, and safety of this program in a 10 week pilot randomized controlled trial (RCT). In this trial, we will enroll 36 participants with bipolar I/II depression, and randomly assign them to either: 1) the yoga intervention, delivered as an adjunct to treatment as usual; or 2) treatment as usual enhanced with a publicly-available bipolar disorder self-help book (ETAU). In a preliminary fashion, we will examine whether the yoga classes (compared to ETAU) appear promising in terms of reduced symptom severity and improved quality of life.
Capsules formed by coating particulate materials with a substance comprising a gelable hydrophilic colloid by a process involving liquid-liquid phase separation are rendered less permeable by spray drying a dispersion of the coated material in a liquid having a pH between 4 and 6.  The coating material may be a single gelable colloid, e.g. gelatine or it may additionally comprise other colloid material, e.g. partially or completely hydrolysed styrenemaleic anhydride copolymer, gum acacia, sodium alginate, sodium carboxymethyl cellulose or carbohydrate acetate phthalates.  The particulate material may be a lipophilic solid, an oil, or an oil-in-hydrophilic liquid or hydrophilic liquid-in-oil emulsion. Prior to spray drying, the capsules may be hardened, e.g. by treatment with formaldehyde, a dicarbonyl compound, tannic acid or an alum.  Specific examples refer to the spray-drying of capsules including those containing: (a) an aqueous suspension of caffeine-in-mineral oil emulsion (sustained action oral stimulant), (b) aqueous sulphanilamide solution-in-lanolin emulsion (ointment ingredient); (c) particles of mercuric oxide coated with glyceryl mono-stearate (veterinary anthelmintic), and (d) aqueous chloral hydrate-in-mineral oil (sustained action sedative).  Specifications 751,600, 911,483, 929,402, 929,404, 929,405, 929,406, 929,407, 929,408 and 929,409 are referred to.
The new 2024 ESC guidelines on the management of patients with atrial fibrillation (AF) introduces the AF-CARE pathway as the central acronym for AF management. As a result, the management of Comorbidities and risk factors is moving to the forefront of AF management. However, the new guideline also includes important changes in Avoidance stroke and thromboembolism, such as a modified risk score (CHA2DS2-VA) and a statement on anticoagulation in subclinical atrial fibrillation. There are also changes in the concepts of Rhythm and rate control with an upgrading of rhythm control and catheter ablation. Finally, the guideline recommends regular Evaluation and reassessment of the patient's course for optimal AF management. Here, we summarize key points of the new guidelines and discusses some recommendations on aspects that can also be assessed differently.
Bolus Injection: A bolus injection may be used to initiate therapy. The dose should be slowly injected directly into a vein, or the tubing of a suitable administration set, over a period of 3 to 5 minutes (see next paragraph regarding flushing of tubing). 

Infusion: With any intermittent infusion of aztreonam and another drug with which it is not pharmaceutically compatible, the common delivery tube should be flushed before and after delivery of aztreonam with any appropriate infusion solution compatible with both drug solutions; the drugs should not be delivered simultaneously. Any aztreonam for injection infusion should be completed within a 20- to 60-minute period. With use of a Y-type administration set, careful attention should be given to the calculated volume of aztreonam solution required so that the entire dose will be infused. A volume control administration set may be used to deliver an initial dilution of aztreonam for injection (see Preparation of Parenteral Solutions: Intravenous Solutions: For Infusion) into a compatible infusion solution during administration; in this case, the final dilution of aztreonam should provide a concentration not exceeding 2% w/v.
PURPOSE: Little is known about the long-term and functional prognoses of older adults with pneumonia, which complicates their management. There is a common belief that aspiration is a poor prognostic factor; however, the diagnosis of aspiration pneumonia (AP) lacks consensus criteria and is mainly based on clinical characteristics typical of the frailty syndrome. Therefore, the poor prognosis of AP may also be a result of frailty rather than aspiration. This study investigated the impact of AP and other prognostic factors in older patients with pneumonia.
METHODS: We performed a retrospective cohort study of patients aged 75 years and older, admitted with pneumonia in 2021. We divided patients according to their initial diagnosis (AP or non-AP), compared outcomes using Kaplan-Meier curves, and used logistic regression to identify independent prognostic factors.
RESULTS: 803 patients were included, with a median age of 84 years and 52.7% were male. 17.3% were initially diagnosed with AP. Mortality was significantly higher in those diagnosed with AP than non-AP during admission (27.6% vs 19.0%, p = 0.024) and at 1 year (64.2% vs 53.1%, p = 0.018), with survival analysis showing a median survival time of 62 days and 274 days in AP and non-AP, respectively (χ2 = 9.2, p = 0.002). However, the initial diagnosis of AP was not an independent risk factor for poor prognosis in multivariable analysis. Old age, frailty and cardio-respiratory comorbidities were the main factors associated with death.
CONCLUSION: The greater mortality in AP may be a result of increased frailty rather than the diagnosis of aspiration itself. This supports our proposal for a paradigm shift from making predictions based on the potentially futile labelling of AP or non-AP, to considering frailty and overall condition of the patient.
Intervention arm participants will receive: 1) the ACS exercise and diet guidelines; and 2) an exercise outcome expectation workbook. The workbook contains self-directed activities to increase OE importance, certainty, and accessibility. The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many positive exercise outcomes breast cancer survivors may experience. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes.
PURPOSE:A bath or hair liquid that contains separated soybean protein and a small amount of soybean lecithin, thus activating the functions of subcutaneous tissues. CONSTITUTION:Over half os nonprotein substances are removed from skin-peeled soybeans of good quality, no defect and fine selection to prepare separated soybean protein. Then, the protein is conbimed with 0.5-5.0wt%, preferably 0.5-1.5wt% of soybean lecithin based on the protein to prepare a skin nutrition composition. the composition is used to giver a bath liquid or hair liquid. Thus, protein of high nutrition can be penetrated into human skins deeply. When it is used in a hair liquid, the skin nutrition composition is dissolved in water in an amount of 0.5-5.0wt%, preferably 1.0-2.0wt%.
One and a half hour sessions (6 sessions) of cognitive behavioural therapy and psychoeducation. The sessions will consist of: sleep hygiene, cognitive therapy, bedtime restriction, stimulus control and relaxation.
This is a prospective, open, dose-exploring clinical study of Lutetium \[177Lu\]-FAP-75 in the treatment of patients with advanced solid tumors. The study was divided into two stages, the first stage was dose exploration study, and the second stage was case expansion study. In the first phase of this study, several dose groups were designed. Subjects may receive only one of these doses and may not receive multiple doses in the same subject. The drug was administered every 6 weeks, and the DLT observation period was 6 weeks after the first dose. Firstly, the first dose safety introduction of human body was carried out. Based on the results of the preclinical study of this product, an appropriate number of enrolled subjects in the first and second stages were selected to enter the PK and radiation dosimetry detection groups. After the end of the DLT observation period, subjects who met the criteria for continued dosing were allowed to continue to receive the investigational drug therapy for subsequent cycles. For all participants enrolled in this study, the study process included a screening period, a treatment period and a follow-up period. In the course of the trial, extended studies of other tumor species can be conducted based on new advances and results of clinical studies of similar drugs to further explore the safety, tolerability and initial effectiveness of specific tumor types.